Share This Post

Focus in RCC shifts to new frontline strategies

From OncLive

Three recent drug approvals have shifted the landscape in the second-line setting for renal cell carcinoma (RCC), and researchers are now setting their sights on transforming upfront care, according to Chung-Han (Joe) Lee, MD

See more at:


Share This Post

Dena Battle is the President and cofounder of KCCure.

Lost Password


Subscribe for updates!